Partenaires

CNRS


Rechercher


Accueil > Publications > Recherche par années > Années 1990 > 1993

Grillon, C ; Bonnet, D ; Mary, JY ; Lenfant, M ; Najman, A ; Guigon, M

The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in-vitro toxicity of 3’-azido-3’-deoxythymidine to human hematopoietic progenitors

Stem Cells 11 (5) 455-464

par Administrateur - publié le , mis à jour le

Abstract :

3’-azido-3’-deoxythymidine (AZT), the main antiviral drug used in AIDS treatment, is known to induce anemia and neutropenia. These effects have been attributed to its toxicity to hematopoietic progenitors. In this report, we present a new approach to reduce AZT hematotoxicity by using an inhibitory factor of the hematopoietic stem cells, the tetrapeptide AcSerAspLvsPro (AcSDKP, Seraspenide), which has been shown to increase the survival of mice subjected to high doses of chemotherapy and to block reversibly the cycling of human granulocyte-macrophage colony forming unit (CFU-GM) and burst forming unit erythroid (BFU-E) progenitors.